Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

Overview

The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.

Full Title of Study: “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: November 1, 2003

Interventions

  • Drug: lamotrigine

Clinical Trial Outcome Measures

Primary Measures

  • % change from Baseline in average monthly PGTC seizure frequency

Secondary Measures

  • Proportion of subjects with >/= 25%, 50%, 75% or 100% reduction in PGTC seizures %change from Baseline in average monthly seizure frequency.

Participating in This Clinical Trial

Inclusion Criteria

  • Weigh at least 13kg.
  • Have a confident diagnosis of epilepsy with primary generalized tonic-clonic (PGTC) seizures with or without other generalized seizure types.
  • Currently being treated with an antiepileptic drug(s) (AED).
  • Benzodiazepines are allowed with some frequency restrictions.
  • Vagus nerve stimulation is allowed if in place for at least 6 months prior to starting the study with no changes to the settings having occured during the month immediately prior to starting the study, and if no changes will occur during all phases of the study.
  • History of primary generalized tonic-clonic seizures with no focal onset.
  • Have at least 1 primary generalized tonic-clonic (PGTC) seizure during the 8 consecutive weeks prior to the baseline period of the study.
  • Have at least 3 PGTC seizures occur anytime during the 8-week baseline phase of the study.
  • Females must agree to acceptable form of birth control.

Exclusion Criteria

  • A history of partial seizures or interictal expression of partial seizures as evidenced by electroencephalogram.
  • Have Lennox-Gastaut syndrome.
  • Currently using or has previously used the drug being studied.
  • Is abusing alcohol and/or other substance(s).
  • Has taken an investigational drug during the 30 days prior to the study or plans to take an investigational drug anytime during the study.
  • Is receiving chronic (long-term) treatment with any medication that could influence seizure control.
  • Follows the ketogenic diet.
  • Is planning surgery to control seizures during the study.
  • Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormality.
  • Has any clinically significant heart, kidney, or liver condition, or a condition that affects how drugs are absorbed, distributed, metabolized, or removed from the body.

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline

Citations Reporting on Results

Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005 Dec 13;65(11):1737-43.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.